All In Biotech

Drug Trial Radar · NCT01076582

Comparative Trial in Hormone Withdrawal Associated Symptoms

A Multi-centre, Randomized, Double-blind, Active Control, Parallel-group, 2-arm Study to Investigate the Effect of Ethinylestradiol / Drospirenone (0.02 mg/3 mg) Oral Contraception in a 24/4 Regimen Compared to Ethinylestradiol / Desogestrel (0.02 mg/0.15 mg) Oral Contraception in a 21/7 Regimen on Hormone Withdrawal Associated Symptoms in Otherwise Healthy Women After 4 Cycles of Treatment

Last checked: Nov 20, 2026Latest source record: Oct 28, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 592 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

592

Actual

Start

Apr 2010

Primary completion

Oct 2011

Study completion Oct 2011

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Feb 26, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical research study will examine whether an oral contraceptive pill taken with a monthly hormone-free interval of 4 days reduces hormone withdrawal associated symptoms compared to an oral contraceptive pill taken with a monthly hormone-free interval of 7 days after 4 cycles of treatment.

Conditions

  • Oral Contraceptive

Interventions

  • EE20/DRSP (YAZ, BAY86-5300)Drug

    4 cycles of treatment / per cycle: 1 tablet (EE 0.02 mg / DRSP 3 mg) daily for 24 days followed by 1 placebo tablet daily for 4 days

  • Ethinylestradiol (EE) and desogestrel (DSG) (Mercilon)Drug

    4 cycles of treatment / per cycle: 1 tablet (EE 0.02 mg / DSG 0.15 mg) daily for 21 days followed by 1 placebo tablet daily for 7 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline to cycle 4 in the sum of composite score during cycle days 22 - 28. The composite score comprises headache, pelvic pain and bloating (each measured by 7-point Likert scales).Time frame: Cycle days 22 - 28 of baseline cycle and cycle 4.

Locations

44 sites in 14 countries. Site status is shown where the registry gives one.

  • Site not named

    Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

  • Site not named

    Rosario, Santa Fe Province, Argentina

  • Site not named

    Santiago, Chile

  • Site not named

    Santiago, Chile

  • Site not named

    Temuco, Chile

  • Site not named

    Santiago, Santiago Metropolitan, Chile

  • Site not named

    Santiago, Santiago Metropolitan, Chile

  • Site not named

    Bogotá, Colombia

  • Site not named

    Medellín, Colombia

  • Site not named

    Bucaramanga, Santander Department, Colombia

  • Site not named

    Brno, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Tábor, Czechia

  • Site not named

    Heidelberg, Baden-Wurttemberg, Germany

  • Site not named

    Fürth, Bavaria, Germany

  • Site not named

    Hanover, Lower Saxony, Germany

  • Site not named

    Leipzig, Saxony, Germany

  • Site not named

    Magdeburg, Saxony-Anhalt, Germany

  • Site not named

    Jena, Thuringia, Germany

  • Site not named

    Florence, Italy

  • Site not named

    Milan, Italy

  • Site not named

    Siena, Italy

  • Site not named

    Manila, Philippines

  • Site not named

    Pasig, Philippines

  • Site not named

    Coimbra, Portugal

  • Site not named

    Porto, Portugal

  • Site not named

    Lisbon, Lisbon District, Portugal

  • Site not named

    Moscow, Russia

  • Site not named

    Moscow, Russia

  • Site not named

    Moscow, Russia

  • Site not named

    Seoul, South Korea

  • Site not named

    Seoul, South Korea

  • Site not named

    Seoul, Korea, South Korea

  • Site not named

    Seoul, Korea, South Korea

  • Site not named

    Basel, Canton of Basel-City, Switzerland

  • Site not named

    Bern, Canton of Bern, Switzerland

  • Site not named

    Sankt Gallen, Canton of St. Gallen, Switzerland

  • Site not named

    Bangkok, Thailand

  • Site not named

    Bangkok, Thailand, Thailand

  • Site not named

    Songkhla, Thailand, Thailand

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.